Daewoong Pharmaceutical announced on July 25th that its premium botulinum toxin, \u2018Nabota,\u2019 has secured an export contract to Kuwait, further strengthening its position in the Middle Eastern market.<\/p>\n
This deal marks Daewoong\u2019s fifth entry into the Middle East and the fourth within the Gulf Cooperation Council (GCC) countries. After establishing a presence in the UAE, Saudi Arabia, and Qatar, the company is now expanding into Kuwait, reinforcing its influence in the Gulf region\u2019s high-end cosmetic and plastic surgery markets.<\/p>\n
Kuwait, with a per capita GDP of around $32,000 and a well-developed healthcare system, presents a promising growth opportunity for the healthcare industry. The country\u2019s strong ties with neighboring Gulf nations make it a strategic hub for future expansion across the Middle East. Daewoong plans to use Kuwait as a gateway to supply Nabota throughout the entire GCC market.<\/p>\n
Currently, Daewoong is the Korean botulinum toxin company with the broadest Middle Eastern reach, leveraging not only product exports but also comprehensive strategies such as medical staff training, academic collaborations, and research initiatives.<\/p>\n
The company continues to innovate with proprietary techniques like combination procedures and the \u2018Naboreift\u2019 program, hosting conferences, webinars, and training sessions to demonstrate the quality and safety of Nabota. Collaborative research with local medical professionals further substantiates Nabota\u2019s efficacy, fostering a \u2018WIN-WIN-WIN\u2019 model that benefits companies, practitioners, and patients.<\/p>\n
Junsu Yoon, Head of Nabota Business at Daewoong, stated, \u201cExpanding into Kuwait signifies Nabota\u2019s growing recognition as a leading brand in the Middle East\u2019s premium neurotoxin market. With robust clinical data and differentiated procedures, we aim to rapidly extend our influence across the entire Middle East region.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Daewoong Pharmaceutical announced on July 25th that its premium botulinum toxin, \u2018Nabota,\u2019 has secured an export contract to Kuwait, further strengthening its position in the Middle Eastern market. This deal marks Daewoong\u2019s fifth entry into the Middle East and the fourth within the Gulf Cooperation Council (GCC) countries. After establishing a presence in the UAE, […]<\/p>\n","protected":false},"author":2,"featured_media":1164,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[216,215],"class_list":{"0":"post-1163","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-industry-news","8":"tag-daewoong-pharmaceutical","9":"tag-daewoong-pharmaceutical-expands-middle-east-presence-with-kuwaiti-export-agreement-for-premium-botulinum-toxin-nabota"},"yoast_head":"\n